Glycart
Latest round
- Series A
Last raised
- Nov 2003
Total raised
- $15M
Investors
- 7
About Glycart
Founded in 2000 in Schlieren, Switzerland, Glycart specializes in antibody-based therapeutics. In July 2005, Roche acquired Glycart, integrating its innovative technologies into its extensive portfolio. The acquisition was part of Roche's strategy to enhance its capabilities in targeted cancer treatments.Roche is a leading global healthcare company that specializes in pharmaceuticals and diagnostics, offering a comprehensive portfolio of innovative products designed to address significant medical needs. Their core product offerings include targeted therapies, biologics, and diagnostics solutions that focus on the prevention, detection, and treatment of diseases, particularly in areas such as oncology, immunology, infectious diseases, and neuroscience. Roche's flagship products include drugs like Herceptin and Avastin, which are pivotal in cancer treatment, and diagnostic tools such as the cobas series of analyzers that enhance disease detection and management.Roche generates revenue primarily through the sale of its pharmaceutical and diagnostic products to healthcare providers, hospitals, and laboratories. The transaction structure typically involves direct sales to these entities or through partnerships with wholesalers and distributors who facilitate product access across different markets. Given that Roche offers both prescription medications and diagnostic solutions, their revenue model encompasses both B2B transactions, supplying hospitals and clinics directly, as well as potential contracts with governmental and private healthcare systems. The company’s revenue is significantly bolstered by its flagship products and ongoing partnerships that focus on advancing research and development within the healthcare sector.Glycart, now a part of Roche, will benefit from ongoing research initiatives to develop new antibody-based therapies targeting various cancers. The company plans to leverage Roche’s resources to expand its product pipeline, aiming to launch new immunotherapy treatments in the next few years. The recent acquisition, finalized in July 2005, allows Roche to utilize Glycart's innovative approaches and technologies to enhance its presence in the oncology market, thereby driving future growth opportunities.
Who invested in Glycart
7 investors across 1 round
See all investors in Glycart
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Nov 26, 2003
Amount
$15M
Investors
Questions about Glycart
Who invested in Glycart?
Glycart has 7 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Glycart raised?
Glycart has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Glycart last raise money?
Glycart's most recent round on record is a Series A, in Nov 2003.
What does Glycart do?
Founded in 2000 in Schlieren, Switzerland, Glycart specializes in antibody-based therapeutics.
Where is Glycart headquartered?
Glycart is headquartered in Schlieren, Switzerland.
Which VCs invest in companies like Glycart?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Highland Europe back biotechnology companies at Glycart's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Glycart? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.